​

Enveric Biosciences (ENVB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ENVB Stock Rating

Enveric Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

ENVB Price Target Upside V Benchmarks

TypeNameUpside
StockEnveric Biosciences-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%
IdeaPsychedelic Stocks List99.60%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.12$7.12$7.12
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 251----1
May, 251----1
Apr, 251----1
Mar, 251----1
Nov, 24-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.09$-19.04----
Avg Forecast$-122.45$-31.20$-21.15$-26.25$-9.30$-3.60
High Forecast$-121.40$-31.20$-21.15$-26.25$-9.30$-3.60
Low Forecast$-123.50$-31.20$-21.15$-26.25$-9.30$-3.60
Surprise %-93.39%-38.97%----

Revenue Forecast

$10M $13M $16M $19M $22M $25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$10.00M$10.00M$15.00M$25.00M
High Forecast--$10.00M$10.00M$15.00M$25.00M
Low Forecast--$10.00M$10.00M$15.00M$25.00M
Surprise %------

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.29K$-9.57M----
Avg Forecast$-264.38M$-67.36M$-45.66M$-56.68M$-20.08M$-7.77M
High Forecast$-262.11M$-67.36M$-45.66M$-56.68M$-20.08M$-7.77M
Low Forecast$-266.64M$-67.36M$-45.66M$-56.68M$-20.08M$-7.77M
Surprise %-99.99%-85.79%----

ENVB Forecast FAQ

Is Enveric Biosciences stock a buy?

Enveric Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Enveric Biosciences is a favorable investment for most analysts.

What is Enveric Biosciences's price target?

Enveric Biosciences's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $7.12.

How does Enveric Biosciences stock forecast compare to its benchmarks?

Enveric Biosciences's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%), trailing the Psychedelic Stocks List (99.60%) investment idea.

What is the breakdown of analyst ratings for Enveric Biosciences over the past three months?

  • June 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Enveric Biosciences’s EPS forecast?

Enveric Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-21.15, marking a 11.08% increase from the reported $-19.04 in 2024. Estimates for the following years are $-26.25 in 2026, $-9.3 in 2027, and $-3.6 in 2028.

What is Enveric Biosciences’s revenue forecast?

Enveric Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $10M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10M, followed by $15M for 2027, and $25M for 2028.

What is Enveric Biosciences’s net income forecast?

Enveric Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-45.664M, representing an 376.91% increase from the reported $-9.575M in 2024. Projections indicate $-56.675M in 2026, $-20.079M in 2027, and $-7.773M in 2028.